Fortis Group Advisors’s INmune Bio INMB Stock Holding History

Fortis Group Advisors’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$103K	Buy	+10,000	New	+$102K	0.02%	196

Other funds holding INMB

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Fortis Group Advisors's INMB Position: Q3 2020 in Review

Fortis Group Advisors opened a new position in INmune Bio (INMB) in Q3 2020: 10,000 shares worth $103K. The stake represents 0.02% of the portfolio and ranks #196 among its holdings.

28 funds tracked by Wall St. Rank hold INMB as of Q3 2020.

Fortis Group Advisors held 10,000 shares of INmune Bio worth $103K as of Q3 2020.
INmune Bio was a new Fortis Group Advisors position in Q3 2020.
INmune Bio made up 0.02% of Fortis Group Advisors's portfolio in Q3 2020, its #196 holding.
28 funds tracked by Wall St. Rank held INmune Bio as of Q3 2020.

Based on Fortis Group Advisors's 13F filing for Q3 2020, filed 17 Nov 2020.